Tanshinone IIA combined with cisplatin synergistically inhibits non‐small‐cell lung cancer in vitro and in vivo via down‐regulating the phosphatidylinositol 3‐kinase/Akt signalling pathway

Cisplatin represents one of the first‐line drugs used for non‐small‐cell lung cancer treatment. However, considerable side effects and the emergence of drug resistance are becoming critical limitations to its application. Combinatorial strategies may be able to extend the use of cisplatin. Both Tans...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Phytother Res
Autores principales: Liao, Xiao‐Zhong, Gao, Ying, Huang, Sheng, Chen, Zhuang‐Zhong, Sun, Ling‐Ling, Liu, Jia‐Hui, Chen, Han‐Rui, Yu, Ling, Zhang, Jia‐Xing, Lin, Li‐Zhu
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6772065/
https://ncbi.nlm.nih.gov/pubmed/31268205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ptr.6392
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares